{"name":"Diffusion Pharmaceuticals","slug":"diffusion","ticker":"DFFN","exchange":"NASDAQ","domain":"diffusionpharma.com","description":"Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) is a publicly traded biotechnology and drug development company based in Charlottesville, Virginia, U.S. It was co-founded in 2001 by American life sciences entrepreneur David Kalergis and University of Virginia Chemical Engineering Professor John L. Gainer. Gainer is the inventor of the company's platform technology of oxygen diffusion-enhancing compounds and its lead drug, trans sodium crocetinate (TSC). TSC acts to increase the rate at which oxygen moves through blood plasma by the process of diffusion, a phenomenon that forms the basis for the company's name. On January 8, 2016, the formerly privately held company merged with Restorgenex Corporation to become a publicly traded NASDAQ-listed company with the trading symbol DFFN. TSC and other oxygen diffusion-enhancing compounds, including bipolar trans carotenoid salts, have been investigated by Diffusion Pharmaceuticals for treatment of conditions associated with reduced oxygen availability in tissues (hypoxia). Most recently, Diffusion has begun the initiation of clinical trials in the U.S. and Eastern Europe for the use of trans sodium crocetinate in the treatment of COVID-19 patients with respiratory distress-related oxygen deficiency and the risk of multiple organ failure.","hq":"Charlottesville, VA","founded":0,"employees":"","ceo":"David Kalergis","sector":"Oncology / Neurology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$18M","metrics":{"revenue":4006510,"revenueGrowth":-58.9,"grossMargin":0,"rdSpend":21817072,"netIncome":-26966367,"cash":22879018,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-28","type":"earnings","headline":"Diffusion Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results","summary":"Diffusion Pharmaceuticals reported its financial results for the fourth quarter and full year 2022, with a net loss of $4.3 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2022-06-15","type":"deal","headline":"Diffusion Pharmaceuticals Announces $10 Million Registered Direct Offering","summary":"Diffusion Pharmaceuticals announced a registered direct offering of $10 million in gross proceeds to support the development of its lead product, Trans Sodium Crocetide (TSC).","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-13","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: FORM 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-01-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-12-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE93aUlIU0VVbXFzZFFJMmhZcndUX1lTdTN6ZXlSejZVS0I1OFFPSkZaVk52X25SVnlReVc1UFlpLUpUZXBUYXdSdjVEaTkwZFIyOEdZ?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"DFFN Stock Price, News & Analysis - Stock Titan","headline":"DFFN Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOVGRnZzJ3Sk4xbERtOGc0eUpFSVJqQm9wOHFtcHlTME1RMzZ6bzdibXVBbHE5QTA1TEdNUTNOT1NsMUlQS0VMTXdWLWl4Y2NkUjNBOF9ZUy12S251eGpxV0dVaHBWUE9pV3VaNmh4SXBVUy1oMVF1aUctZ2FBS19ublh2b0dIdXpzWmJ6ZVZTYVRtbmszcnhKR213VUh4SnlF?oc=5","date":"2023-08-15","type":"regulatory","source":"Yahoo Finance","summary":"Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma - Yahoo Finance","headline":"Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxQcm1MQUd5REdtenBCSUZOS1V1TEZJQndERGw0LWxfTlZVWFk0YThVa040UXRaU1ZTZUN2ZVV2VUxuNzFoWV9RV0xlYmZodmNBZEJjT1hnZ3RwV3VBZC1UNTBRX1kyNnh2MWhRWTlTY1VfRDdTOVAxNHBYQ01MUW1iaG1tVFJIQnVYNGV5cWZsenVWWlY4b244UHF6VUFYNEFjck96STVqNU5UNGRsc0lvSW5UTkNWb1NYUU1XeURBRGtPQy1rTTRaLUIxdjlmYlZqc3RSeHhZU1dBR1dPQkJ4ckY4VFBYV0h6UTFtWGZ4ZHpnSWlzUVZBaTBDUllsS3JVYk1IUW9VeGFOZ0l5Skdma3M1a2FuclBXaWdHNWNrSjlvelhLM3U1cUw2djVhVlluc05jZFp1aw?oc=5","date":"2023-03-30","type":"deal","source":"GlobeNewswire","summary":"EIP Pharma and Diffusion Pharmaceuticals Announce Merger - GlobeNewswire","headline":"EIP Pharma and Diffusion Pharmaceuticals Announce Merger","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiSEFVX3lxTE4zNnVONGticEpTQnlyYkdwVThweW9BNTYyelVMRk9QQUJ5OWVNMWdjb1ZqVy1zWVY1Z2ZSdzdwS3dXX1ExRElmUg?oc=5","date":"2020-12-02","type":"deal","source":"StockInvest.us","summary":"Diffusion Pharmaceuticals Stock Price Forecast. Should You Buy DFFN? - StockInvest.us","headline":"Diffusion Pharmaceuticals Stock Price Forecast. Should You Buy DFFN?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOMW10ZDRvR3ppU01lUS1keHM2V01wdjJwdWJlYjdyVUg4RE53TkZyMnp0dHdIbVVpMTR6b3ZfZnNfOHdqNWFlYTlzOWQwWmZKbUlUbUVudlA0MHRsWEFSWHJJS0lyb3BTbzNMaHN2SENiQTJxWlBCWXAyY251VkgzNjNpaXdJR0s1ODZTV2pUSVg3cVhwOGY1U0RWY2EtS1dfMUF4MDgxYUQ?oc=5","date":"2018-04-30","type":"pipeline","source":"investingnews.com","summary":"8 Glioblastoma Treatment Stocks - investingnews.com","headline":"8 Glioblastoma Treatment Stocks","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Celldex Therapeutics","Immunomedics","Celgene"],"therapeuticFocus":["Oncology","Neurology"],"financials":{"source":"sec_edgar+yahoo","revenue":4006510,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":4006510,"period":"2025-12-31"},{"value":9737974,"period":"2024-12-31"},{"value":9737974,"period":"2024-12-31"},{"value":7144872,"period":"2023-12-31"},{"value":7144872,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":21817072,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-26966367,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":22879018,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}